Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Treatment options for patients with Hodgkin lymphoma who progress after brentuximab vedotin

Alex Herrera • 29 Sep 2022
SOHO 2022
Hodgkin Lymphoma Lymphoma Antibodies Azacitidine Brentuximab vedotin Camidanlumab tesirine CAR-T NK-Cell Therapy

Alex Herrera, MD, City of Hope, Duarte, CA, discusses treatment options for patients with Hodgkin lymphoma (HL) who progress after brentuximab vedotin or PD1 blockade, including epigenetic modifying agents, antibody drug conjugates (ADCs) such as camidanlumab tesirine, and other cellular therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex Herrera

1:26
The safety and efficacy of alloSCT following CAR-T cell therapy for large B-cell lymphoma
Alex Herrera • 29 Sep 2022
0:53
An update on camidanlumab tesirine in HL
Alex Herrera • 29 Sep 2022
0:54
Atezolizumab with R-GEMOX in patients with transformed DLBCL
Alex Herrera • 13 Dec 2021
1:15
Pembrolizumab plus vorinostat in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
Alex Herrera • 13 Dec 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals